Carolyn Y. Johnson

Washington, D.C.

Science reporter

Education: Amherst College, BA in Physics and English; MIT, MS in Science Writing

Carolyn Johnson is a science reporter. She previously covered the business of health, the pharmaceutical industry and the affordability of health care to consumers. Before coming to the Post, she covered science at the Boston Globe.
Latest from Carolyn Y. Johnson

FDA advisers favor retiring original covid shot and using newer version

The original coronavirus shot would be retired in favor of one that targets both the original strain of the coronavirus and the omicron variant.

January 26, 2023

Earth’s inner core seems to be slowing its spin

This isn’t the beginning of the end times. Instead, the findings stoke debate about how the core influences some of the most fundamental parts of our planet.

January 23, 2023

36 bodies were found in unmarked colonial graves. DNA is revealing their stories.

Human remains were unearthed during a construction project in Charleston in 2013. Genetic research revealed they were enslaved people from diverse parts of Africa.

January 9, 2023

Antibody drugs could target infectious diseases — if costs come down

A steady stream of promising studies have identified antibody drugs that could prevent malaria, treat a hemorrhagic fever called Lassa or block Zika.

January 3, 2023

How China’s vaccine strategy stoked its looming ‘zero covid’ crisis

The nation's “zero covid” restrictions have created a crisis for a country with large numbers of older, vulnerable people who have never had a booster shot.

December 1, 2022

Why the 5.6-magnitude earthquake in Indonesia was so deadly

Scientists who study earthquakes offer several factors that could have contributed to the tragic death toll of this relatively mild temblor.

November 22, 2022

Moderna says new booster increases protection from omicron subvariants

The shot increased the levels of antibodies that block the latest coronavirus subvariant.

November 14, 2022

Pfizer says new booster shot increases omicron-fighting antibodies

Questions persist about the vaccine’s continued effectiveness against a swarm of later-generation versions of omicron.

November 4, 2022

What you need to know about covid boosters and the latest research

Two new studies suggest that rebooted coronavirus booster shots that were updated to match two omicron subvariants are not superior to the old boosters.

November 2, 2022

Pfizer’s RSV vaccine, given during pregnancy, protects infants from severe illness

Pfizer plans to apply for approval of its RSV vaccine by year's end, in hopes a vaccine could be available before next year's respiratory-illness season.

November 1, 2022